Tell your U.S. senators: Stop prescription drug patent abuse
Testimony: Better resourced patent examination can improve drug price competition
How newly proposed patent fees can help and in one case possibly hurt access to generics and biosimilar drugs
Download Testimony below
Patricia Kelmar, PIRG’s senior director for health care campaigns, testified before the U.S. Patent and Trademark office on May 18, 2023. She explained how the agency can align their proposed fee schedule with public interest priorities.
- Improving patent examination can help ferret out anticompetitive practices such as “patent thicketing” that keeps generic and biosimilar drugs off the market. Without competing therapeutically equivalent drugs competing with brand-name drugs, medication prices remain high.
- Increasing fees for the inter-partes review (IPR) system could make it financially impossible for the public to challenge weak patents.
Download the testimony at the link above to read more.
And share your story about high drug prices here.
Topics
Authors
Patricia Kelmar
Senior Director, Health Care Campaigns, PIRG
Patricia directs the health care campaign work for U.S. PIRG and provides support to our state offices for state-based health initiatives. Her prior roles include senior director of health policy with the National Consumers League, senior policy advisor at NJ Health Care Quality Institute, and advocate at AARP and NJPIRG. She serves on the Ground Ambulance and Patient Billing Advisory Committee at the Centers for Medicare and Medicaid Services. Patricia enjoys walks along the Potomac River and sharing her love of books with her friends and family around the world.
Find Out More
Proliferation of medical credit cards raise concerns about increasing medical debt
The Cost of Prescription Drug Patent Abuse
Video Explainer: Why can’t I get a generic version of my drug?